Amicus Therapeutics Is Maintained at Buy by UBS
Amicus Therapeutics Is Maintained at Buy by UBS
Amicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ...
Express News | Amicus Therapeutics Inc : UBS Cuts Target Price to $19 From $20
Amicus Therapeutics Is Maintained at Buy by B of A Securities
Amicus Therapeutics Is Maintained at Buy by B of A Securities
Express News | B of A Securities Maintains Buy on Amicus Therapeutics, Lowers Price Target to $13
Express News | Needham Reiterates Hold on Amicus Therapeutics
Amicus Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 — Needham Reiterates → Hold 03/18/2024 101.48% JP Morgan $21 → $19 Maintains Overweight 02/29/
Express News | Amicus Therapeutics Inc : Leerink Partners Cuts Target Price to $17 From $18
Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Amicus Therapeutics | 10-Q: Quarterly report
Express News | Amicus Therapeutics Shares Are Trading Lower Following Mixed Q1 Earnings
Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise
Amicus Therapeutics (FOLD) reported a Q1 non-GAAP net loss Thursday of $0.02 per diluted share, compared with a loss of $0.06 a year earlier. Analysts surveyed by Capital IQ expected a loss of $0.03.
Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
Express News | Amicus Therapeutics Inc: Guiding to Full-Year 2024 Total Revenue Growth of 25%-30% at Cer
Express News | Amicus Therapeutics Inc: Raising Full-Year 2024 Galafold(®) Guidance on Continued Strong Demand
Express News | Amicus Therapeutics Inc: Reiterating Full-Year Non-Gaap Profitability Projected in 2024
Express News | Amicus Forecasts 2024 Total Revenue Growth Of 25%-30%, With Galafold Revenue Growth Of 13%-17%
Express News | Amicus Therapeutics Q1 2024 Adj EPS $(0.02) Beats $(0.07) Estimate, Sales $110.403M Miss $111.186M Estimate
Express News | Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
Express News | Amicus Therapeutics Q1 Revenue USD 110.4 Million Vs. Ibes Estimate USD 111.2 Million
No Data